发布求助
文献互助 智能选刊 最新文献

Immuno-Oncology and Technology最新文献

筛选
英文 中文
190P Immune-related roles of B7H3 in glioblastoma 190P B7H3 在胶质母细胞瘤中的免疫相关作用
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100649
A. Simonet, D. Isci, V. Neirinckx, G. Jerusalem, B. Rogister
{"title":"190P Immune-related roles of B7H3 in glioblastoma","authors":"A. Simonet, D. Isci, V. Neirinckx, G. Jerusalem, B. Rogister","doi":"10.1016/j.iotech.2023.100649","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100649","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138612883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091 120MO 对于切除术和可选化疗后的早期 NSCLC，pembrolizumab 与安慰剂的辅助治疗：PEARLS/KEYNOTE-091的最新结果
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100592
B. Besse, L. Havel, S. Peters, S. Marreaud, N. Jha, K. Oselin, E. Esteban González, M. Isla Casado, A. Martínez-Martí, M. Faehling, J.-S. Lee, Y. Luo, S.M. Keller, U. Dafni, M.E. Mauer, R. Stahel, M.E.R. O'Brien, M. Tsuboi, L. Paz-Ares
{"title":"120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091","authors":"B. Besse, L. Havel, S. Peters, S. Marreaud, N. Jha, K. Oselin, E. Esteban González, M. Isla Casado, A. Martínez-Martí, M. Faehling, J.-S. Lee, Y. Luo, S.M. Keller, U. Dafni, M.E. Mauer, R. Stahel, M.E.R. O'Brien, M. Tsuboi, L. Paz-Ares","doi":"10.1016/j.iotech.2023.100592","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100592","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138613308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
148P HexaBody-OX40: A novel Fcγ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo 148P HexaBody-OX40：一种不依赖 Fcγ 受体交联的新型 OX40 靶向抗体，具有体外激动活性和体内抗肿瘤活性
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100620
K. Kemper, M. Köhne, M. van der Kroef, K. Nuermberger, M. Russier, G. Zom, Anna-Lena Krause, P. de Goeje, F. Gieseke, A. Gorlani, A. Muik, L. Guelen, D. Satijn, S. Fellermeier-Kopf, T. Ahmadi, Ö. Türeci, E. Breij, U. Şahin
{"title":"148P HexaBody-OX40: A novel Fcγ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo","authors":"K. Kemper, M. Köhne, M. van der Kroef, K. Nuermberger, M. Russier, G. Zom, Anna-Lena Krause, P. de Goeje, F. Gieseke, A. Gorlani, A. Muik, L. Guelen, D. Satijn, S. Fellermeier-Kopf, T. Ahmadi, Ö. Türeci, E. Breij, U. Şahin","doi":"10.1016/j.iotech.2023.100620","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100620","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138615847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
180P Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas 180P 随机 NeoPembrOv 临床试验的免疫基因组分析表明，VEGFR2 血管生成轴是克服高级别卵巢癌免疫抗体的可行靶点
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100639
O. Le Saux, M. Ardin, J. Berthet, M. Bourhis, I. Treilleux, P-A. Just, G. Bataillon, A.M. Savoye, M-A. Mouret-Reynier, E. Coquan, O. Derbel, S. Bouizaguen, S.I. Labidi-Galy, E. Tartour, I. Galy-Fauroux, M-H. Stern, M. Terme, C. Caux, B. Dubois, I. Ray-Coquard
{"title":"180P Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas","authors":"O. Le Saux, M. Ardin, J. Berthet, M. Bourhis, I. Treilleux, P-A. Just, G. Bataillon, A.M. Savoye, M-A. Mouret-Reynier, E. Coquan, O. Derbel, S. Bouizaguen, S.I. Labidi-Galy, E. Tartour, I. Galy-Fauroux, M-H. Stern, M. Terme, C. Caux, B. Dubois, I. Ray-Coquard","doi":"10.1016/j.iotech.2023.100639","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100639","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138618911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
168P Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC 168P 化疗加放疗的序列治疗对激活 SCLC 先天性免疫的影响
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100627
C. de Rosa, C. Tuccillo, L. Amato, F. Ciardiello, V. Nardone, F. Morgillo, C. Della Corte
{"title":"168P Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC","authors":"C. de Rosa, C. Tuccillo, L. Amato, F. Ciardiello, V. Nardone, F. Morgillo, C. Della Corte","doi":"10.1016/j.iotech.2023.100627","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100627","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 45","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
140P Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform 140P 利用新型抗体发现平台诱导针对 MHC 结合肽的 mAbs
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100612
E. Sandberg, J.P. Verdi, N. Papavasiliou
{"title":"140P Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform","authors":"E. Sandberg, J.P. Verdi, N. Papavasiliou","doi":"10.1016/j.iotech.2023.100612","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100612","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 48","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
182P Exploring cross-compartmental tumor cell plasticity and immunogenicity in serous ovarian cancer 182P 探索浆液性卵巢癌中肿瘤细胞的跨区可塑性和免疫原性
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100641
L.S. Hell, T. Sturmheit, L. Oliveira-Ferrer, Y. Ding, C. Pellens, K. Eylmann, M. Rossberg, W.M. Fiedler, J. Kupper, B. Schmalfeldt, F. Brauneck, J. Wellbrock
{"title":"182P Exploring cross-compartmental tumor cell plasticity and immunogenicity in serous ovarian cancer","authors":"L.S. Hell, T. Sturmheit, L. Oliveira-Ferrer, Y. Ding, C. Pellens, K. Eylmann, M. Rossberg, W.M. Fiedler, J. Kupper, B. Schmalfeldt, F. Brauneck, J. Wellbrock","doi":"10.1016/j.iotech.2023.100641","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100641","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
161TiP A phase I/II, open-label study of an anti-ILT2 (LILRB1) antibody, SAR444881, administered alone and in combination with pembrolizumab, with or without chemotherapy, or cetuximab in patients with advanced solid tumors 161TiP 一项针对晚期实体瘤患者的抗 ILT2 (LILRB1) 抗体 SAR444881 单药或与 pembrolizumab（无论有无化疗）或西妥昔单抗联合用药的 I/II 期开放标签研究
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100672
R. Perets, S. Stemmer, R. Geva, T. Golan, M. Fakih, J. Cohen, C. Lieu, Z. Jin, P. Lorusso, N. Ashtamker, I. Friedman, M. Hakim, N. Crawford, R. Perez, M. Agarwal, G. Abbadessa, M. Wu, J. Lin, C. Deantonio, M. Borad
{"title":"161TiP A phase I/II, open-label study of an anti-ILT2 (LILRB1) antibody, SAR444881, administered alone and in combination with pembrolizumab, with or without chemotherapy, or cetuximab in patients with advanced solid tumors","authors":"R. Perets, S. Stemmer, R. Geva, T. Golan, M. Fakih, J. Cohen, C. Lieu, Z. Jin, P. Lorusso, N. Ashtamker, I. Friedman, M. Hakim, N. Crawford, R. Perez, M. Agarwal, G. Abbadessa, M. Wu, J. Lin, C. Deantonio, M. Borad","doi":"10.1016/j.iotech.2023.100672","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100672","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":"79 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138622047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC) 157TiP Krascendo-170 肺癌：一项针对未经治疗的 KRAS G12C+ 晚期非小细胞肺癌 (NSCLC) 的 divarasib + pembrolizumab ± 铂类化疗和培美曲塞的 Ib/II 期研究
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100668
F. Skoulidis, K. Cuppens, A. Sacher, V. Velcheti, D.H. Lee, M.T. Lin, T.M. Fernando, S. Li, D. Bradley, M. Z. Crnkovic, M.S. Mathisen
{"title":"157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)","authors":"F. Skoulidis, K. Cuppens, A. Sacher, V. Velcheti, D.H. Lee, M.T. Lin, T.M. Fernando, S. Li, D. Bradley, M. Z. Crnkovic, M.S. Mathisen","doi":"10.1016/j.iotech.2023.100668","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100668","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":"118 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138622505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
174P Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity 174P 靶向巨噬细胞中的 SPHK1 可抑制结直肠癌的肝转移，并使抗肿瘤免疫与免疫疗法毒性脱钩
Immuno-Oncology and Technology Pub Date : 2023-12-01 DOI: 10.1016/j.iotech.2023.100633
Y. Zhan, Z. Shen, G. Li, Y. Fang
{"title":"174P Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity","authors":"Y. Zhan, Z. Shen, G. Li, Y. Fang","doi":"10.1016/j.iotech.2023.100633","DOIUrl":"https://doi.org/10.1016/j.iotech.2023.100633","url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":"1 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138623812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信